LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol

Photo by ksamashott from unsplash

CONTACT INFORMATION Mahtab et al., 2016. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naïve Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLOS… Click to show full abstract

CONTACT INFORMATION Mahtab et al., 2016. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naïve Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLOS ONE 2016; 11: e156667 Martin M. Cutadapt removes adapter sequences from high throughput sequencing reads. EMBnet.journal 2011; 17: 10 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60 Töpfer A et al. Probabilistic inference of viral quasispecies subject to recombination. J. Comput. Biol.2013; 20: 113-23 Felsenstein J. PHYLIP—phylogeny inference package. Cladistics 1989; 5: 164–166 Infection with hepatitis B virus (HBV) may lead to acute or chronic hepatitis. Globally, 240 million people are chronically infected with HBV, and approximately 1 million people die annually from HBV-related diseases.

Keywords: determinant rep; absence mutations; hbsag determinant; 2139 therapy; rep 2139; mutations hbsag

Journal Title: Journal of Hepatology
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.